Polio vaccine is usually provided in vials containing 10–20 doses of vaccine. A single dose of oral polio vaccine (usually two drops) contains 1,000,000 infectious units of Sabin 1 (effective against PV1), 100,000 infectious units of the Sabin 2 strain, and 600,000 infectious units of Sabin 3. The vaccine contains small traces of antibiotics—neomycin and streptomycin—but does not contain preservatives. In a generic sense, vaccination works by priming the immune system with an 'immunogen'. Stimulating immune response, by use of an infectious agent, is known as immunization. The development of immunity to polio efficiently blocks person-to-person transmission of wild poliovirus, thereby protecting
Sabin Vaccine Institute Africa, and the Americas. Sabin is currently working on multiple vaccines for humans including vaccines for Hookworm infection ("Na"-GST-1, "Na"-APR-1), Schistosomiasis ("Sm"-TSP-2), Chagas disease ("Tc"24, TSA-1), Leishmaniasis ("Ld"-NH36, PdSP15), Severe acute respiratory syndrome (SARS)/Middle East respiratory syndrome (MERS) (Pan-β-CoVax), Soil-transmitted helminthiasis (STH), and Onchocerciasis (Ov-"103", Ov-"RAL-2"). In 2006, Sabin co-founded the Global Network for Neglected Tropical Diseases in order "to raise the awareness, political will and funding necessary to control and eliminate the most common NTDs." Through its work on NTDs, Sabin hopes to reduce poverty caused by these diseases as many of them have been shown to adversely affect